UAB "Droplet Genomics" Finance - revenue, profit
EBITDA margin (%)
Register and
explore Okredo dataEBIT margin (%)
Register and
explore Okredo data| Indicator |
|---|
| Turnover (€) |
| Sales per employee (€) |
| Profit before tax (€) |
| Net Profit (€) |
| Profit per employee (€) |
| Total profitability (%) |
| Net profitability (%) |
| Equity (€) |
| Amounts Payable And Liabilities (€) |
| Non-current Assets (€) |
| CurrentAssets (€) |
| Working capital requirement |
| Debt-to-equity ratio |
| EBITDA margin (%) |
| EBITDA (€) |
| EBIT margin (%) |
| EBIT (€) |
| 2021 |
|---|
| 870,777 |
| 42,539 |
| 57,870 |
| 57,870 |
| 2,827 |
| 78.84 |
| 6.65 |
| -178,748 |
| 1,176,255 |
| 214,146 |
| 834,640 |
| 0.81 |
| -6.58 |
| - |
| - |
| 13.63 |
| 118,718 |
| 2022 |
|---|
| 1,931,408 |
| 66,212 |
| -34,810 |
| -34,810 |
| -1,193 |
| 80.99 |
| -1.80 |
| 878,566 |
| 4,193,960 |
| 381,529 |
| 4,705,688 |
| 0.26 |
| 4.77 |
| - |
| - |
| 1.80 |
| 34,859 |
| 2023 |
|---|
| 2,845,771 |
| 56,632 |
| -1,429,854 |
| -1,429,854 |
| -28,455 |
| 81.32 |
| -50.24 |
| 3,628,287 |
| 289,738 |
| 449,032 |
| 3,596,593 |
| 1.11 |
| 0.08 |
| - |
| - |
| -48.97 |
| -1,393,504 |
| 2023 |
|---|
| 2,845,771 |
| 56,632 |
| -1,429,854 |
| -1,429,854 |
| -28,455 |
| 81.32 |
| -50.24 |
| 3,628,287 |
| 289,738 |
| 449,032 |
| 3,596,593 |
| 1.11 |
| 0.08 |
| - |
| - |
| -48.97 |
| -1,393,504 |
Turnover (€)
2023
Turnover (€)
2,845,771 €47 % *
Sales per employee (€)
56,632 €-14 % *
Profit before tax (€)
-1,429,854 €-4,008 % *
Net Profit (€)
-1,429,854 €-4,008 % *
Profit per employee (€)
-28,455 €-2,285 % *
Total profitability (%)
81.32 %0.41 % *
Net profitability (%)
-50.24 %-2,691.11 % *
Equity (€)
3,628,287 €313 % *
Amounts Payable And Liabilities (€)
289,738 €-93 % *
Non-current Assets (€)
449,032 €18 % *
CurrentAssets (€)
3,596,593 €-24 % *
Working capital requirement
1.11 326.92 % *
Debt-to-equity ratio
0.08 -98.32 % *
EBITDA margin (%)
-EBITDA (€)
-EBIT margin (%)
-48.97 %-2,820.56 % *
EBIT (€)
-1,393,504 €-4,098 % *
